Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Expenditures (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Capital Expenditures for 4 consecutive years, with $71000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 136.67% to $71000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $480000.0 through Dec 2025, up 77.78% year-over-year, with the annual reading at $480000.0 for FY2025, 77.78% up from the prior year.
  • Capital Expenditures hit $71000.0 in Q4 2025 for Axsome Therapeutics, up from $58000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $371000.0 in Q3 2023 to a low of $7000.0 in Q4 2023.
  • Historically, Capital Expenditures has averaged $127125.0 across 4 years, with a median of $80500.0 in 2023.
  • Biggest YoY gain for Capital Expenditures was 462.12% in 2023; the steepest drop was 96.13% in 2023.
  • Year by year, Capital Expenditures stood at $181000.0 in 2022, then tumbled by 96.13% to $7000.0 in 2023, then soared by 328.57% to $30000.0 in 2024, then soared by 136.67% to $71000.0 in 2025.
  • Business Quant data shows Capital Expenditures for AXSM at $71000.0 in Q4 2025, $58000.0 in Q3 2025, and $13000.0 in Q2 2025.